factual
Negative net present value drives pharma exit
A London School of Economics study found that a big pharmaceutical company investing in a new antibiotic faces a net present value of negative $50 million—an expected loss—which is why companies are bundling and selling off their anti-infective units and why the 75-year government-pharma partnership is dissolving.
factualpending
Speaker
Matt McCarthyEvidence Quote
“the net present value is negative $50 million they can expect to lose that much money”
Created: 6/14/2026, 2:12:29 AM
Your notes
Loading notes...